Recursion Pharmaceuticals
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage TechBio company that aims to revolutionize drug discovery and development by integrating artificial intelligence (AI) and machine learning with high-throughput automated wet-lab biology. The company’s proprietary platform, known as the Recursion Operating System (OS), generates, analyzes, and interprets massive biological and chemical datasets. This approach allows Recursion to explore novel biology, identify potential drug candidates, and advance them through development with increased speed and efficiency compared to traditional methods.
The Recursion OS is powered by proprietary multimodal data, purpose-built AI models, and bilingual teams proficient in both science and AI. It leverages robotics and computer vision to conduct millions of cell experiments weekly, feeding results back into the system for continuous improvement. The company has also built an in-house supercomputer, BioHive-1, and is developing BioHive-2 with NVIDIA, to train and deploy advanced AI models in computational biology and chemistry. Recursion’s pipeline includes investigational medicines in oncology, rare diseases, neuroscience, and immunology, with several programs in clinical stages. They also engage in strategic partnerships with major pharmaceutical companies like Bayer, Roche, Genentech, and Sanofi to expand their impact.
Recursion’s mission is to decode biology to radically improve lives by making drug discovery more programmable, data-driven, and scalable. They focus on indications with high unmet medical needs, such as familial adenomatous polyposis (FAP), advanced solid tumors, and hypophosphatasia. The company’s approach addresses key failure points in traditional R&D, including efficacy, safety, and clinical success, by using AI to map biology, generate chemistry, and simulate patient outcomes.
Focus Areas
Business Intelligence
| Key Investors | Felicis Ventures, DCVC, Advantage Capital, Lux Capital, Leaps by Bayer, Casdin Capital, Catalio Capital Management, LP, Laurion Capital Management, Samsara BioCapital, Baillie Gifford, Mubadala, ARCH Venture Partners, Obvious Ventures, EPIC Ventures, Two Sigma Ventures, Intermountain Ventures, NVIDIA |
| Partnerships | Roche, Genentech, Sanofi, Bayer, Merck KGaA, NVIDIA, Google Cloud, Helix, Tempus, Citeline |
| Acquisitions | Cyclica, Valence, Exscientia |
| Technology | Recursion Operating System (OS), a full-stack, AI-native platform integrating automated wet labs, high-throughput cellular imaging (Cell Painting assay), deep learning, and a supercomputer (BioHive-2) to generate and analyze proprietary biological and chemical datasets (>60 petabytes). |
| FDA Clearances | 2 (IND clearances for REC-994 and REC-1245) cleared products (estimated) |
What Physicians Need to Know
Recursion Pharmaceuticals' approach offers several potential benefits for physicians. Their AI-driven platform aims to accelerate the discovery and development of novel medicines, potentially leading to new treatment options for diseases with high unmet needs, particularly in oncology and rare diseases. The company's focus on generating massive, high-quality biological and chemical datasets and using advanced AI to analyze them may lead to a deeper understanding of disease biology and more precisely designed therapies. Physicians may see the impact of this in faster identification of drug candidates and potentially improved efficacy and safety profiles due to the platform's ability to predict drug interactions and toxicity earlier in the development process. Recursion also emphasizes well-designed clinical trials and transparency, which can provide valuable data for treatment decisions.
Recursion Pharmaceuticals actively pursues strategic partnerships with leading pharmaceutical companies (e.g., Roche/Genentech, Bayer, Sanofi, Merck KGaA) and technology partners (e.g., NVIDIA, Google Cloud, Tempus, Helix). These collaborations are crucial for expanding their therapeutic reach, scaling and improving their AI drug discovery platform, accessing diverse datasets (including de-identified patient data), and securing non-dilutive funding. For physicians, this indicates a collaborative ecosystem that aims to integrate cutting-edge AI with established pharmaceutical expertise and real-world patient data, potentially leading to more robust and clinically relevant drug development.
What the Web Says
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses AI and automation to accelerate drug discovery and development. Their platform, Recursion OS, integrates automated cell biology experiments, large-scale phenomics imaging, and foundation models to identify drug candidates. While the company is considered a leader in AI-driven drug discovery with significant partnerships, it has yet to bring an approved product to market and faces challenges with profitability and a demanding work culture.
Overall: MixedStrengths
- Closed-loop integration of wet-lab experiments with AI models continuously improves prediction accuracy.
- Proprietary biological datasets spanning petabytes of experimental data enable novel target discovery.
- AI-powered virtual screening accelerates hit identification by 10-100x compared to traditional high-throughput screening.
- Strategic pharma partnerships validate platform capabilities with billion-dollar deal values.
- Generous benefits and pay for employees.
- Mission-driven organization with a strong culture of inclusiveness and teamwork.
Limitations
- Requires substantial proprietary training data to achieve meaningful prediction accuracy improvement.
- Enterprise pricing is accessible only to large pharma, making it prohibitive for academic labs and small biotechs.
- Long sales cycles and custom integration requirements extend time to value for new customers.
- Black-box nature of deep learning models creates interpretability challenges for regulatory submissions.
- Poor work-life balance and demanding work environment, with reports of unpaid overtime and layoffs.
- Lack of mature leadership and concerns about transparency and communication from management.
- No approved products on the market yet, and no candidates in Phase 3 studies.
- Ongoing operating losses and significant share dilution, with profitability likely several years away.
Based on reviews from: Indeed.com, Biology Digital, Reddit, The Motley Fool, Seeking Alpha, DirectorsTalk Interviews, Comparably
Last updated: 2026-06-23
Videos
News, demos, and interviews about Recursion Pharmaceuticals.
Videos load interactively. If none appear, search YouTube for Recursion Pharmaceuticals →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Recursion Pharmaceuticals.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]